{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rilpivirine+%28RPV%29+tablet",
    "query": {
      "intervention": "Rilpivirine (RPV) tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rilpivirine+%28RPV%29+tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T22:04:24.354Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00799864",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Abacavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 54,
      "start_date": "2011-01",
      "completion_date": "2022-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 2,
      "location_summary": "Syracuse, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799864"
    },
    {
      "nct_id": "NCT02422797",
      "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG 50 mg",
          "type": "DRUG"
        },
        {
          "name": "RPV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "CAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2015-04-21",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 13,
      "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422797"
    },
    {
      "nct_id": "NCT02605954",
      "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "Third Antiretroviral Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2015-11-18",
      "completion_date": "2018-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605954"
    },
    {
      "nct_id": "NCT02741557",
      "title": "Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "RPV",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2016-05-11",
      "completion_date": "2016-10-24",
      "has_results": false,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02741557"
    },
    {
      "nct_id": "NCT02345226",
      "title": "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/RPV/TAF",
          "type": "DRUG"
        },
        {
          "name": "EFV/FTC/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "EFV/FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 881,
      "start_date": "2015-01-26",
      "completion_date": "2019-01-02",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 79,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345226"
    },
    {
      "nct_id": "NCT02616029",
      "title": "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2015-12-17",
      "completion_date": "2019-07-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-23",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 3,
      "location_summary": "Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616029"
    },
    {
      "nct_id": "NCT05917509",
      "title": "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG/3TC",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir (CAB) LA",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine (RPV) LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2023-07-06",
      "completion_date": "2026-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05917509"
    },
    {
      "nct_id": "NCT03497676",
      "title": "More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Oral Cabotegravir (CAB)",
          "type": "DRUG"
        },
        {
          "name": "Oral Rilpivirine (RPV)",
          "type": "DRUG"
        },
        {
          "name": "Long-Acting Injectable Cabotegravir (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Long-Acting Injectable Rilpivirine (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "Combination Antiretroviral Therapy (cART)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 168,
      "start_date": "2019-04-03",
      "completion_date": "2025-04-22",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497676"
    },
    {
      "nct_id": "NCT02373930",
      "title": "Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "DTG 50 mg",
          "type": "DRUG"
        },
        {
          "name": "RPV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV 50 mg/25 mg: Product Code AS",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV 50 mg/25 mg: Product Code AM",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV 50 mg/25 mg: Product Code AQ",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV 50 mg/25 mg: Product Code AK",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV 50 mg/25 mg: Product Code AR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 63,
      "start_date": "2015-02",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02373930"
    },
    {
      "nct_id": "NCT02345252",
      "title": "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/RPV/TAF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 632,
      "start_date": "2015-01-26",
      "completion_date": "2019-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-09-28T22:04:24.354Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345252"
    }
  ]
}